UPDATE: Brinson Patrick Initiates Vical at Market Outperform on Allovectin Potential
In a report published Monday, Brinson Patrick analyst Vernon Bernardino initiated coverage on Vical (NASDAQ: VICL) with a Market Outperform rating and $7.00 price target.
In the report, Brinson Patrick noted, “We are initiating coverage of Vical with a Market Outperform rating and 12-month price target of $7. We believe Vical's lead product, Allovectin, is poised to be a significant driver of the company's shares, beginning in 2Q13 with database lock of its Allovectin in metastatic melanoma Phase III trial. We believe the results will be positive, positioning Vical with a blockbuster opportunity in the rapidly evolving melanoma market.”
Vical closed on Friday at $2.93.
Latest Ratings for VICL
|Aug 2013||Canaccord Genuity||Downgrades||Buy||Hold|
|Aug 2013||Credit Suisse||Downgrades||Outperform||Neutral|
© 2014 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.